)
NEWS
Media Contacts:
Seqirus news releases
Seqirus news releases
First cell-based quadrivalent influenza vaccine approved for use in Europe
This news release is intended for Health Professional media only.
Seqirus Announces U.S. $140 Million Manufacturing Expansion to Meet Growing Demand for Innovative Cell-Based Influenza Vaccines
The expansion will allow Seqirus to increase capacity for formulation, fill and finish manufacturing of cell-based and adjuvanted influenza vaccines for global markets.
New Data on Cell-Based Seasonal Influenza Vaccines
This news release is intended for Health Professional media only.
Seqirus Cell-based Influenza Vaccine Nears European Approval
Subject to final approval by the European Commission, Seqirus plans to launch the vaccine as FLUCELVAX® TETRA1 in Europe for the 2019/20 influenza season.
Seqirus Joining UIVI to Advance Universal Flu Vaccine Research
Human Vaccines Project and Seqirus Partner to Advance Universal Flu Vaccine Research
New PNG Snakebite Project to Improve Access to Antivenoms
The project is intended to significantly improve access to antivenoms by combining a large antivenom donation, healthcare worker training, with a purpose-built distribution and product management system.